High baseline level of pre-existing CD8 + T cells as well as increase in tumor infiltrating CD8 + T cells during treatment has been found to be associated with better response of patients treated with anti-PD-1 therapy (Tumeh et al., 2014; Daud et al., 2016). The gene discussed is PDCD1; the disease is neoplasm.